---
document_datetime: 2025-05-23 20:03:03
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lacosamide-ucb-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lacosamide-ucb-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5993947
conversion_datetime: 2025-12-28 00:19:22.707155
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lacosamide UCB

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | B.IV.1.a Addition or replacement of a device | 16/05/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000265278                     | which is not an integrated part of the primary packaging - B.IV.1.a.1 Device with CE marking - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |                                  |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|
| Variation type IB / EMA/VR/0000266348 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - to align the English Product Information with latest QRD templates (10.3 and 10.4). Thus, section 9 and 10 of the SmPC were updated. Minor editing errors were amended in Annex II and in the Labelling and minor inaccurate information was removed from the Package Leaflet. The MAH took the opportunity to update the contact details of the local representative for Iceland in section 6 of the Package Leaflet. According to QRD 10.4, contact details for UK (NI) were deleted. Furthermore, updates in all EU languages were performed with additional minor linguistic adjustments in BG, HR, CS, NL, ET, FR, DE, HU, IT, LV, LT, MT, PL, SK, SL, ES and SV annexes. | 12/05/2025 |     | SmPC, Annex II, Labelling and PL |
| Variation type IA / EMA/VR/0000248925 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 07/03/2025 | N/A |                                  |

<div style=\"page-break-after: always\"></div>

| substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Refused A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|